CureVac initially expected to seek European approval for its jab in the second quarter, with Germany pencilling in 1.4 million doses by end-June. Lucha, whose state is home to CureVac’s Tübingen headquarters, told local media there were “complications” with the trial. The German Health Ministry declined to comment further, but said once the vaccine is greenlit “we will include CureVac in the campaign”. Despite being a laggard in the vaccine race, CureVac believes it has advantages over its mRNA competitors. The European Union has secured up to 405 million doses of the CureVac vaccine.

Source: The Local June 11, 2021 14:15 UTC